Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
Matthieu MILLION, Jean-Christophe LAGIER, Hervé TISSOT-DUPONT, Isabelle RAVAUX, Catherine DHIVER, Christelle TOMEI, Nadim CASSIR, Léa DELORME, Sébastien CORTAREDONA, Sophie AMRANE, Camille AUBRY, Karim BENDAMARDJI, Cyril BERENGER, Barbara DOUDIER, Sophie EDOUARD, Marie HOCQUART, Morgane MAILHE, Coralie PORCHETO, Piseth SENG, Catherine TRIQUET, Stéphanie GENTILE, Elisabeth JOUVE, Audrey GIRAUD-GATINEAU, Herve CHAUDET, Laurence CAMOIN-JAU, Philippe COLSON, Philippe GAUTRET, Pierre-Edouard FOURNIER, Baptiste MAILLE, Jean-Claude DEHARO, Paul HABERT, Jean-Yves GAUBERT, Alexis JACQUIER, Stéphane HONORE, Katell GUILLON-LORVELLEC, Yolande OBADIA, Philippe PAROLA, Philippe BROUQUI, Didier RAOULT
Table 1. Death rate according to treatment and age.
All HCQ+AZ Other treatments
N % N % n %
N 16/10,429# 0.15 5/8315 0.06 11/2114 0.52
Male sex 4832/10,429 46.33 3914/8315 47.07 918/2114 43.42
Age interval (years)
18–29 0/2157 0.00 0/1752 0.00 0/405 0.00
30–39 0/2004 0.00 0/1650 0.00 0/354 0.00
40–49 0/2074 0.00 0/1692 0.00 0/382 0.00
50–59 0/2179 0.00 0/1726 0.00 0/453 0.00
>59 16/2015 0.79 5/1495 0.33 11/520 2.21
60–69 4/1286 0.31 2/1003 0.20 2/283 0.71
70–79 6/555 1.08 1/395 0.25 5/160 3.13
80–89 6/158 3.80 2/93 2.15 4/65 6.15
>89 0/16 0.00 0/4 0.00 0/12 0.00
HCQ, Hydroxychloroquine; AZ, Azithromycin.
#An additional death occurred that was unrelated to COVID-19 or treatment but was not included in the analyses because no information can be described for forensic reasons.